Bavarian Nordic A/S said on Monday that Paul Chaplin will vacate his post as chief executive officer for personal reasons. The company said Chaplin will continue in the role through the end of 2026 or until a successor is found, and that the Board of Directors has launched a search for a new CEO.
Chaplin has been with Bavarian Nordic since 1999 and was elevated to the CEO role in 2014. During his time at the helm, he guided the company through the development of its smallpox and mpox vaccine programs. Under his direction, Bavarian Nordic expanded from a small research-focused organisation with a single government customer into a vaccine manufacturer operating commercially in key markets.
In a statement, Chaplin reflected on his tenure: "I am leaving Bavarian Nordic with great pride. I have truly enjoyed the experiences and professional challenges over nearly three decades and have had the privilege of leading many talented colleagues towards a shared mission of improving and saving lives. We have achieved a lot and created a strong foundation for the future of the company."
Chaplin also said his family intends to move back to Australia. He added: "My family wants to relocate back to Australia, but I remain fully committed to the company for the remainder of the year to allow for a stable transition to its next CEO." The company release and Chaplin's comments together indicate both a longer transition horizon - through the end of 2026 or until a successor is identified - and a personal timeline reference to the remainder of the year.
The board's announcement signals the start of a formal process to identify Chaplin's successor. The statement did not provide additional details about the search process, potential internal candidates, or any interim leadership arrangements.
As the company moves forward, market participants and stakeholders in the biotech and vaccine manufacturing sectors will be watching for updates from Bavarian Nordic about the search timeline and the profile of the next CEO. The company's recent evolution under Chaplin - from a research-oriented firm with a single government client to a commercially active vaccine producer - is a central element of the narrative accompanying the leadership transition.